ORAMED PHARMACEUTICALS INC.
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
ORMP$4.00+3.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS
| September 30, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| CURRENT ASSETS: | ||
| Cash and cash equivalents | $52,179 | $54,420 |
| Short-term deposits | 4,038 | 55,281 |
| Marketable securities | 4,956 | 3,441 |
| Investments at fair value | 73,514 | 28,788 |
| Prepaid expenses and other current assets | 1,430 | 1,291 |
| Total current assets | 136,117 | 143,221 |
| LONG-TERM ASSETS: | ||
| Long-term deposits | 2 | 2 |
| Investments at fair value | 11,410 | 7,387 |
| Investment in associate at fair value | 64,803 | - |
| Loan to an equity method investee | 1,044 | - |
| Investment in real estate | 2,122 | - |
| Other non-marketable equity securities | 3,524 | 3,524 |
| Amounts funded in respect of employee rights upon retirement | 40 | 32 |
| Property and equipment, net | 614 | 698 |
| Operating lease right-of-use assets | 817 | 414 |
| Total long-term assets | 84,376 | 12,057 |
| Total assets | $220,493 | $155,278 |
| Liabilities and stockholders’ equity | ||
| CURRENT LIABILITIES: | ||
| Accounts payable and accrued expenses | $4,861 | $5,140 |
| Payable to related parties | 1 | 329 |
| Deferred income | 986 | - |
| Operating lease liabilities | 271 | 216 |
| Total current liabilities | 6,119 | 5,685 |
| LONG-TERM LIABILITIES: | ||
| Long-term deferred revenues | 2,000 | 4,000 |
| Long-term deferred income | 1,496 | - |
| Employee rights upon retirement | 38 | 30 |
| Operating lease liabilities | 589 | 156 |
| Other liabilities | - | 60 |
| Deferred tax liabilities | 7,921 | - |
| Total long-term liabilities | 12,044 | 4,246 |
| COMMITMENTS (note 9) | ||
| EQUITY ATTRIBUTABLE TO COMPANY’S STOCKHOLDERS: | ||
| Common stock, $0.012 par value (60,000,000 authorized shares; 40,838,226 and 39,919,545 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively) | 490 | 480 |
| Additional paid-in capital | 325,367 | 322,401 |
| Accumulated deficit | (122,575) | (176,616) |
| Total stockholders’ equity | 203,282 | 146,265 |
| Non-controlling interests | (952) | (918) |
| Total equity | 202,330 | 145,347 |
| Total liabilities and equity | $220,493 | $155,278 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.